As an ex-pharma employee I tend nowadays to be more interested in his work extending the infrastructure for health delivery, and the reach of drugs which need expensive R&D to develop, into areas of the world that otherwise the commercial model couldn’t reach.
Anyway, this blog is written on a Mac …
ITasITis 